US Patent

US10016393 — Stabilized pharmaceutical dosage forms comprising atrasentan

Formulation · Assigned to AbbVie Inc · Expires 2034-07-07 · 8y remaining

Vulnerability score 38/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects methods for using and preparing stabilized pharmaceutical dosage forms containing atrasentan or a pharmaceutically acceptable salt thereof.

USPTO Abstract

The present disclosure relates to: (a) methods of using stabilized pharmaceutical dosage forms comprising atrasentan, or a pharmaceutically acceptable salt thereof, and, optionally, another therapeutic agent to treat type 2 diabetes, microalbuminuria or macroalbuminuria; and (b) methods for the preparation of such pharmaceutical dosage forms.

Drugs covered by this patent

Patent Metadata

Patent number
US10016393
Jurisdiction
US
Classification
Formulation
Expires
2034-07-07
Drug substance claim
No
Drug product claim
Yes
Assignee
AbbVie Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.